Dementia with Lewy bodies can be challenging to diagnose correctly and is subsequently underdiagnosed. Neuroimaging is often used to aid clinicians make the diagnosis. Here the authors describe a case where a patient was misdiagnosed with the condition due to their antidepressant therapy influencing their scan result.
{"title":"Misdiagnosis of dementia with Lewy bodies due to venlafaxine","authors":"M. Kanani, Nhishanth Gurunathan","doi":"10.1002/pnp.742","DOIUrl":"https://doi.org/10.1002/pnp.742","url":null,"abstract":"Dementia with Lewy bodies can be challenging to diagnose correctly and is subsequently underdiagnosed. Neuroimaging is often used to aid clinicians make the diagnosis. Here the authors describe a case where a patient was misdiagnosed with the condition due to their antidepressant therapy influencing their scan result.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48299985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bethany Wildridge, S. Rozewicz, A. Mohamed, J. James, Gerard Connolly
The degenerative nature of Huntington's disease drastically reduces quality of life for sufferers while limiting life expectancy itself. Among other sequalae, psychosis and chorea remain persistently difficult disease manifestations to manage for patients. Clozapine is an atypical antipsychotic medication with a multineuroreceptor affinity, which gives it a broad range of action. Clozapine has been documented to have good remedial actions on chorea and psychosis in patients with Huntington's disease. Here the authors make the case for further research.
{"title":"Use of clozapine for psychosis and chorea in Huntington's disease systematic narrative review","authors":"Bethany Wildridge, S. Rozewicz, A. Mohamed, J. James, Gerard Connolly","doi":"10.1002/pnp.750","DOIUrl":"https://doi.org/10.1002/pnp.750","url":null,"abstract":"The degenerative nature of Huntington's disease drastically reduces quality of life for sufferers while limiting life expectancy itself. Among other sequalae, psychosis and chorea remain persistently difficult disease manifestations to manage for patients. Clozapine is an atypical antipsychotic medication with a multineuroreceptor affinity, which gives it a broad range of action. Clozapine has been documented to have good remedial actions on chorea and psychosis in patients with Huntington's disease. Here the authors make the case for further research.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42439671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gone are the days when neurologists considering disease modifying therapy for their patients with relapsing remitting multiple sclerosis (RRMS) could only access a handful of agents that are easy to compare. This charmingly simple situation has rapidly evolved to an increased ability to access a variety of agents that are potentially suitable for the equally complex spectrum of RRMS syndromes with different clinical and radiological features. The approval of ponesimod by NICE as a first‐ or second‐line treatment for RRMS is another welcomed addition to the current agents available.
{"title":"Ponesimod for the treatment of relapsing‐remitting multiple sclerosis","authors":"T. Gaber, M. Eltemamy","doi":"10.1002/pnp.745","DOIUrl":"https://doi.org/10.1002/pnp.745","url":null,"abstract":"Gone are the days when neurologists considering disease modifying therapy for their patients with relapsing remitting multiple sclerosis (RRMS) could only access a handful of agents that are easy to compare. This charmingly simple situation has rapidly evolved to an increased ability to access a variety of agents that are potentially suitable for the equally complex spectrum of RRMS syndromes with different clinical and radiological features. The approval of ponesimod by NICE as a first‐ or second‐line treatment for RRMS is another welcomed addition to the current agents available.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44008937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. A. Asadi-Pooya, Mohsen Farazdaghi, A. Emami, A. Akbari, F. Javanmardi
The link and association between COVID‐19 and Alzheimer's disease (AD) is controversial. This study aims to investigate whether COVID‐19 was associated with a different presenting clinical picture or a more severe course of illness (eg intubation and death) in people with AD in this study cohort.
{"title":"COVID‐19 in patients with Alzheimer's disease","authors":"A. A. Asadi-Pooya, Mohsen Farazdaghi, A. Emami, A. Akbari, F. Javanmardi","doi":"10.1002/pnp.748","DOIUrl":"https://doi.org/10.1002/pnp.748","url":null,"abstract":"The link and association between COVID‐19 and Alzheimer's disease (AD) is controversial. This study aims to investigate whether COVID‐19 was associated with a different presenting clinical picture or a more severe course of illness (eg intubation and death) in people with AD in this study cohort.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49234574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Yahya, Shakil Khawaja, Paul Simon Williams, Meena Naguib
Binge eating disorder (BED) is the most common eating disorder in patients with type 2 diabetes (T2D) but remains underdiagnosed and undertreated. Here, the authors review the latest epidemiological findings and highlight the importance of early intervention and robust screening for BED in those with a diagnosis of T2D. The need for better‐quality studies that focus on the diagnosis, management and prognostic outcomes of BED in T2D is also revealed.
{"title":"Binge eating disorder and type 2 diabetes: epidemiology and treatment approaches","authors":"A. Yahya, Shakil Khawaja, Paul Simon Williams, Meena Naguib","doi":"10.1002/pnp.749","DOIUrl":"https://doi.org/10.1002/pnp.749","url":null,"abstract":"Binge eating disorder (BED) is the most common eating disorder in patients with type 2 diabetes (T2D) but remains underdiagnosed and undertreated. Here, the authors review the latest epidemiological findings and highlight the importance of early intervention and robust screening for BED in those with a diagnosis of T2D. The need for better‐quality studies that focus on the diagnosis, management and prognostic outcomes of BED in T2D is also revealed.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49402708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The COVID‐19 pandemic has presented major challenges for all demographics of society. The strict lockdown measures utilised to control the spread of the virus have the potential unintended consequences of exacerbating social isolation and loneliness, which are recognised to be pre‐existing issues in the elderly population. Because of this, the pandemic may have disproportionality impacted the elderly population. One way that the distress caused by the pandemic could manifest is through self‐harm and suicide. Here, the authors present a retrospective, cross‐sectional study examining self‐harm in an older adult population in the south west of England.
{"title":"Self‐harm in an older adult population during the COVID‐19 pandemic","authors":"Michael Obidoa, R. Bello, S. Hardman","doi":"10.1002/pnp.747","DOIUrl":"https://doi.org/10.1002/pnp.747","url":null,"abstract":"The COVID‐19 pandemic has presented major challenges for all demographics of society. The strict lockdown measures utilised to control the spread of the virus have the potential unintended consequences of exacerbating social isolation and loneliness, which are recognised to be pre‐existing issues in the elderly population. Because of this, the pandemic may have disproportionality impacted the elderly population. One way that the distress caused by the pandemic could manifest is through self‐harm and suicide. Here, the authors present a retrospective, cross‐sectional study examining self‐harm in an older adult population in the south west of England.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48273919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Myasthenia gravis (MG) is a rare, long‐term autoimmune disorder that causes muscle weakness; the condition typically has phases when it remits and phases when it relapses. Even though treatment response with regards to immunosuppressive therapies in MG patients is classically monitored by clinical scores, identification of a serological biomarker that monitors treatment response could be helpful. Here, the authors explore the correlation between acetylcholine receptor (AChR) antibody titers with changes in clinical severity in patients with MG and discuss the implications for clinical practice.
{"title":"Changes in antibody titers and clinical course in myasthenia gravis retrospective study","authors":"B. Berger, Nils Schröter","doi":"10.1002/pnp.738","DOIUrl":"https://doi.org/10.1002/pnp.738","url":null,"abstract":"Myasthenia gravis (MG) is a rare, long‐term autoimmune disorder that causes muscle weakness; the condition typically has phases when it remits and phases when it relapses. Even though treatment response with regards to immunosuppressive therapies in MG patients is classically monitored by clinical scores, identification of a serological biomarker that monitors treatment response could be helpful. Here, the authors explore the correlation between acetylcholine receptor (AChR) antibody titers with changes in clinical severity in patients with MG and discuss the implications for clinical practice.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46432360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clozapine prescribing in treatment‐refractory schizophrenia is underutilised, including in early intervention for psychosis services. COVID‐19 has brought various challenges to the utilisation of clozapine, particularly in the context of initiation and monitoring. There is a need for clear national guidance in this regard.
{"title":"COVID‐19 and clozapine use in an early intervention for psychosis service","authors":"Rizwana Jafry, Marlene Kelbrick","doi":"10.1002/pnp.737","DOIUrl":"https://doi.org/10.1002/pnp.737","url":null,"abstract":"Clozapine prescribing in treatment‐refractory schizophrenia is underutilised, including in early intervention for psychosis services. COVID‐19 has brought various challenges to the utilisation of clozapine, particularly in the context of initiation and monitoring. There is a need for clear national guidance in this regard.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47515174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Recognition of suicide risk factors in patients presenting with psychotic illness is of the utmost importance. In their study, the authors identified two important issues in the cohort of patients who died of unnatural causes/suicide, highlighting a need for clinicians to be aware of these risk factors and make efforts to establish a therapeutic relationship, providing appropriate support to patients to help them to develop an awareness of their suicide risk and to empower them to resist their suicidal thoughts.
{"title":"Suicide in patients under care of first‐episode psychosis service","authors":"A. Javed, D. Das","doi":"10.1002/pnp.739","DOIUrl":"https://doi.org/10.1002/pnp.739","url":null,"abstract":"Recognition of suicide risk factors in patients presenting with psychotic illness is of the utmost importance. In their study, the authors identified two important issues in the cohort of patients who died of unnatural causes/suicide, highlighting a need for clinicians to be aware of these risk factors and make efforts to establish a therapeutic relationship, providing appropriate support to patients to help them to develop an awareness of their suicide risk and to empower them to resist their suicidal thoughts.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45747226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shamim Asgari, Mbizvo Gashirai, Jennifer Smith, S. Alusi
Seronegative autoimmune limbic encephalitis is a rare clinical syndrome defined by a rapid onset of cognitive impairment with neuropsychiatric features and an absence of associated autoantibodies that often lead to diagnostic uncertainty, delayed treatment and ultimately, poor prognosis. Here a case is presented that highlights the benefits of implementing a multidisciplinary approach to treating the psychiatric manifestations, including a cautious use of therapeutic home leave for patients where the clinical course is prolonged.
{"title":"Seronegative autoimmune limbic encephalitis with psychiatric symptoms","authors":"Shamim Asgari, Mbizvo Gashirai, Jennifer Smith, S. Alusi","doi":"10.1002/pnp.735","DOIUrl":"https://doi.org/10.1002/pnp.735","url":null,"abstract":"Seronegative autoimmune limbic encephalitis is a rare clinical syndrome defined by a rapid onset of cognitive impairment with neuropsychiatric features and an absence of associated autoantibodies that often lead to diagnostic uncertainty, delayed treatment and ultimately, poor prognosis. Here a case is presented that highlights the benefits of implementing a multidisciplinary approach to treating the psychiatric manifestations, including a cautious use of therapeutic home leave for patients where the clinical course is prolonged.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47338047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：